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Background
HD IL-2 is an approved immunotherapy for advanced
melanoma and renal cell carcinoma with a reported
objective response rate (ORR) up to 20%. Patients with
stable disease (SD) following treatment are not consid-
ered objective responders and thus are not included in
reported response rates. Since the initial reports of IL-2
our understanding of the delayed pharmacokinetics of
immunotherapy has improved. The purpose of this
study is to report the clinical outcomes for patients with
stable response to HD IL-2.
Methods
A retrospective chart review of 305 patients diagnosed
with metastatic renal cell carcinoma or melanoma and
treated with HD IL-2 therapy over a 12-year period was
conducted. Age, response to HD IL-2 (based on RECIST
criteria) and survival data were available in 215 patients at
the time of analysis. Survival analysis was conducted on all
patients for whom complete data was available and
Kaplan-Meier curves were generated based on overall
survival.
Results
Among the 215 patients with complete data, 62% had pro-
gressive disease (PD), 24% had SD and the objective
response rate was 14%. Median overall survival was 16.8
months among all 215 patients. Patients with a PR or CR
(median survival not reached in the study period) had sig-
nificantly prolonged survival than the remaining patients
(median survival 13.9 months, log-rank p < 0.01). Patients
with SD (median survival of 38.2 months) had improved
survival compared to patients with progressive disease
(median survival of 7.9 months, log-rank p< 0.01).
Discussion
The IL-2 literature has focused on partial or complete
responders when reporting objective response rates. In
our data, as well as elsewhere in the literature, there are a
large number of patients who have a stable response to
HD IL-2 that have not been included in the ORR. Our
data supports a significant survival benefit associated
with stable disease following IL-2, which suggests that
HD IL-2 may result in a clinical benefit in a larger num-
ber of patients than has previously been reported. Con-
sideration of a disease control rate (DCR) inclusive of
objective responders and stable responses may be more
appropriate to better define the clinical benefit of IL-2.
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